KR20120065248A - Composition for improving, alleviating, treating or preventing of atopic disease - Google Patents

Abstract

PURPOSE: A composition containing ginseng saponin metabolite F2 is provided to relieve inflammation and to reduce IgE concentration in serum. CONSTITUTION: A pharmaceutical composition for preventing or treating atopic dermatitis contains ginseng saponin metabolite F3 as an active ingredient. The composition is manufactured in the form of an ointment, gel, cream, patch, or spray. The composition is used for oral or injection formulation. The oral formulation includes powder, granules, tablets, capsules, suspension, aerosol, suspension, emulsion or syrup. A cosmetic composition for treating or relieving atopic dermatitis contains the ginseng saponin metabolite F2 as an active ingredient.

Description

Composition for improving, alleviating, treating or preventing of atopic disease

The present invention relates to a pharmaceutical composition for improving, alleviating, treating or preventing atopic diseases comprising ginseng saponin metabolite F2 as an active ingredient, and a cosmetic composition for improving or alleviating atopic skin.

Atopy, the Greek word atoto, is used to mean something unusual, strange, or unusual. Literally, a variety of causes are entangled and complicated, recurring and recurring.

Atopic diseases include allergic asthma, allergic conjunctivitis, allergic rhinitis, atopic dermatitis, and these diseases may be present alone or in combination.

The cause of atopic disease known to date is not known exactly, but it is presumed that genetic and immunological factors are commonly involved and other environmental and mental factors are causing deterioration.

Atopic dermatitis is one of the most common skin diseases in infants and children and begins at a rate of 45% during 6 months, 60% before 12 months and at least 85% before 5 years of age. It is usually known as a disease when it is young, but 50% of the patients disappear without symptoms within two stones, but 25% last until adolescence, and the remaining 25% do not go away even when they are adults.

The main symptom of atopic dermatitis is itching. When itchy and scratched, it develops into eczematous lesions, and as the lesion progresses, a series of vicious cycles occur, causing more pruritus.

In addition, the total immunoglobulin E value is increased in more than 80% of patients with atopic dermatitis, and allergic conjunctivitis, allergic rhinitis or allergic asthma patients have high levels of immunoglobulin E.

Currently, the most widely used therapeutic agent for atopic dermatitis is dexamethasone, which is known as a steroid, but it is effective for short-term treatment, and for long-term treatment for more than one year, stability and efficacy are not established and skin thinning or skin atrophy Problems have been reported, such as reports of side effects such as scars, skin discoloration, and the like.

As such, synthetic medicines are not only problematic for long-term use, but are not treated well with one active ingredient. Recently, there is a growing interest in extracts derived from natural products having various active ingredients and functions.

In Korea, the proportion of patents related to atopic dermatitis is about 69% for drugs, 26% for cosmetics, and 5% for foods. Among them, cosmetics has a high proportion of development cases using natural products, which indicates that natural products are widely used for research and development of cosmetics.

Ginseng (Panax ginseng CA Meyer.Ginseng radix) is a perennial herb belonging to the genus Araliaceae ginseng (Panax), which has been used for medicinal purposes for a long time and has been used in medicinal plants for a long time. It is considered as the best health food in the world. The chemical composition of ginseng consists of saponin, essential oils, polyacetylene, phenol, alkaloids, polysaccharides, amino acids, organic acids, free sugars, vitamins and inorganics.

Ginsenoside, which is known as an active ingredient of ginseng, is a major indicator component of ginseng, and about 50 ginsenosides are known in addition to major ginsenosides such as Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rg2, Rg3, and Rh.

Korean Patent Publication No. 2003-0032631, "Cosmetic composition for the treatment of atopic dermatitis" (published on April 26, 2003) Korean Patent Publication No. 2004-0051255, "Cosmetic Composition" (Published June 18, 2004) Korean Patent Laid-Open Publication No. 2008-0002279, "Cosmetics composition for improving the effect of atopic symptoms" (January 4, 2008) Korean Patent Publication No. 2008-0056369, "Cosmetic composition comprising ginseng extract and deep sea water" (Published June 23, 2008)

It is an object of the present invention to provide a pharmaceutical composition for improving, alleviating, treating or preventing atopic diseases.

It is an object of the present invention to provide a cosmetic composition for atopic skin improvement or alleviation.

The present invention provides a pharmaceutical composition for improving, alleviating, treating or preventing atopic diseases comprising ginseng saponin metabolite F2 as an active ingredient.

In another aspect, the present invention provides a cosmetic composition for improving atopic skin relief comprising ginseng saponin metabolite F2 as an active ingredient.

In the present invention, "F2" means "Ginseng saponin metabolite F2".

In the composition of the present invention, F2 refers to a convertor from ginsenosides Rb1, Rb2, Rc or Rd, which is red ginseng saponin, and has a structure as shown in [Formula 1] below.

[Formula 1]

F2 of the present invention is a substance not found in red ginseng is a saponin convertor is produced by a small amount of red ginseng saponin is converted by enterobacteriaceae. For example, F2 is described by Yang et (J. Ginseng Res. Vol. 32, No. 3, 226-231, 2008), Jo et (J. Ginseng Res. Vol. 31, No. 4, 181-190, 2007 It can be prepared by the method described in). In addition, as in the preparation of the present invention, F2 can be obtained by incubating protopanaxadiol type saponins (ginsenosides Rb1, Rb2, Rc and Rd) with Aspergillus niger derived cellulase, and a commercially available product can also be purchased. .

In the present invention, the atopy disease may be at least one selected from atopic dermatitis, allergic asthma, allergic rhinitis and allergic conjunctivitis, which is shown as an immune hypersensitivity reaction, atopic dermatitis is more preferred.

In the present invention, the pharmaceutical composition may be a formulation selected from the group consisting of ointments, gels, creams, patches and sprays. In addition, the pharmaceutical composition may be an oral or injectable preparation.

The oral preparations are powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, suspensions, solutions, emulsions or syrups, and the injectable preparations may be in the form of sterile injectables.

The pharmaceutical composition of the present invention may be formulated by adding a pharmaceutically acceptable carrier, and the formulation may be referred to Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA. The pharmaceutically acceptable carrier refers to those commonly used in preparing pharmaceutical compositions to those skilled in the art. For example, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl Pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. Pharmaceutically acceptable carriers also include diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants and the like. For example, oral solid preparations include tablets, pills, powders, granules, capsules, and the like, including at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin. And the like, and may include a lubricant such as magnesium stearate, talc and the like.

Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include water, diluents such as liquid paraffin, wetting agents, sweeteners, fragrances, preservatives, and the like. Parenteral preparations include sterile aqueous solutions, non-aqueous solvents, suspending agents, emulsions, and lyophilized preparations. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, and vegetable oils such as olive oil and ethyl oleate. Injectable esters such as the like and the like. However, the present invention is not limited to the above-listed pharmaceutically acceptable carriers and the like, which are merely exemplary.

The dosage of ginseng saponin metabolite F2 contained in the pharmaceutical composition depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration, and the duration, and may be appropriately selected in some cases. For example, the ginseng saponin metabolite F2 may be administered at a dose of 0.0001 to 100 mg / kg, preferably 0.01 to 100 mg / kg, and the administration may be administered once or several times a day. have. In addition, the pharmaceutical composition may include 0.0001 to 50% by weight of the ginseng saponin metabolite F2 based on the total weight of the composition. The pharmaceutical compositions can be administered to mammals, such as humans, by various routes, for example by oral, intravenous, intramuscular, or subcutaneous injection.

In addition, the pharmaceutical composition of the present invention may contain one or more active ingredients indicating improvement, alleviation, treatment or prevention of atopic diseases in addition to F2.

In addition, the pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, hormone therapy, drug treatment and biological response modifiers for the improvement, alleviation, treatment or prevention of atopic diseases.

In the present invention, the cosmetic composition is supple cosmetics, astringent cosmetics, nourishing cosmetics, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, It may be a formulation selected from the group consisting of body oils, body essences, makeup bases, foundations, hair dyes, shampoos, rinses and body cleansers.

The cosmetic composition of the present invention may be prepared in various forms using the ginseng saponin metabolite F2 according to a conventional cosmetic preparation method, stabilizers, solubilizers, vitamins, pigments, and the like commonly used in the cosmetic composition field Conventional adjuvants such as flavorings.

In addition, when the cosmetic composition is prepared in the form of a cosmetic product containing the ginseng saponin metabolite F2, shampoo, hair lotion, hair cream, hair gel, etc., it may be used diluted with conventional cleansing liquid, astringent liquid and moisturizing liquid. .

The cosmetic composition of the present invention may contain 0.001% to 20% by weight of the ginseng saponin metabolite F2 based on the total weight of the composition.

Since the composition of the present invention has no irritation to the skin, and has anti-inflammatory activity, inflammation relief and skin barrier improvement, and immune hypersensitivity effect, the pharmaceutical composition for improving, alleviating, treating or preventing atopic diseases and for improving or alleviating atopic skin It can be used as a cosmetic composition.

1 is a chart showing the amount of NO production (inflammatory products) generated when ginseng saponin metabolite F2 was treated to Murine macrophage (Raw 264.7 cell).
Figure 2 is a photograph showing the visual observation results after the application and oral administration of ginseng saponin metabolite F2 to mice induced inflammatory diseases, including atopic dermatitis and immune hypersensitivity.
Figure 3 is a chart showing the results of observation of the number of scratches of the mouse after application and oral administration of ginseng saponin metabolite F2 to mice induced inflammatory diseases, including atopic dermatitis and immune hypersensitivity.
Figure 4 is a photograph showing the histological observations after the application and oral administration of ginseng saponin metabolite F2 to mice induced inflammatory diseases, including atopic dermatitis and immune hypersensitivity.
Figure 5 is a table showing the results of measuring the thickness of the skin epidermal layer after application and oral administration of ginseng saponin metabolite F2 to mice induced inflammatory diseases, including atopic dermatitis and immune hypersensitivity reactions.
Figure 6 is a chart showing the effect of reducing the serum IgE concentration of rats after the application and oral administration of ginseng saponin metabolite F2 in mice induced inflammatory diseases, including atopic dermatitis and immune hypersensitivity.
7 is a chart showing the effect of increasing the concentration of IFN-γ in the serum of rats after the application and oral administration of ginseng saponin metabolite F2 in atopic dermatitis induced rats.
8 is a chart showing the effect of reducing the concentration of IL-4 in the serum of the rat after applying and oral administration of ginseng saponin metabolite F2 to atopic dermatitis induced rats.

Hereinafter, the present invention will be described in more detail with reference to Examples, Experimental Examples and Preparation Examples, but the scope of the present invention is not limited to the following Examples and Experimental Examples.

In the present invention, "F2" means "Ginseng saponin metabolite F2", "F2" used in the present invention used "F2" provided by Dalian University in China.

< Example  1> F2 Raw  264.7 cell through NO  Confirmation of generation suppression

Nitric oxide (NO), produced excessively by stimulation, results in inflammatory diseases. Accordingly, 0.5 ppm of lipopolysaccharide (manufactured by Sigma) dissolved in distilled water that induces an inflammatory response in murine macrophage (Raw 264.7 cell, manufacturer: ATCC) and 10% FBS, which is a culture solution of murine macrophage, are included. 0.1 ppm, 1 ppm, 10 ppm and 50 ppm of F2 dissolved in DMEM were treated for 24 hours, respectively, and the amount of nitrogen monoxide (NO), which is one of the inflammatory products, was determined by measuring absorbance using ELIZA.

Measurement of the NO content in the culture solution produced by treating lipopolysaccharide (Lipopolysaccharide) was carried out using the Griess reaction using nitrite as an indicator of NO production. Add 50 μl of the supernatant cultured to a 96-well plate and add Griess reagent [1% (w / v) sulfanilamide, in 5% (v / v) phosphoric acid and 0.1% (w / v) N- (1-Naphthyl 50 μl of the same mixture of ethylene-diamine dihydrochloride] (v / v, 1: 1, Griess reagent) was added and reacted for 10 minutes. It was. A standard calibration curve was prepared using sodium nitric dioxide (NaNO ₂ ) as a standard to determine the NO production in the culture solution. The results are shown in FIG. 1 and Table 1 below.

[Table 1]

As shown in [Table 1], it was confirmed that ginseng saponin metabolite F2 shows a strong anti-inflammatory action.

(In FIG. 1, the control means a group that does not cause inflammation because LPS (Lipopolysaccharide) is not treated, LPS is a group that induces inflammation by treating only LPS alone, and DEX causes dexamethasone after inflammation with LPS. Means the treated group, the concentration of dexamethasone is 50ppm.)

< Example  2> Evaluation of Atopic Dermatitis Mouse Model Activity

NC / Nga mouse atopy model (7 weeks old, male, 8 per group, Daehan Biolink) was used to examine the relationship between skin inflammation and atopic dermatitis. Mice treated with 1% (10mg / mL) trinitrochlorobenzene (TNCB) for 5 days to induce inflammatory diseases including atopic dermatitis and immune hypersensitivity reactions. Application and oral administration were confirmed to alleviate inflammatory diseases, including atopic dermatitis and immune hypersensitivity. During the animal experiment, the animal cage was kept at a temperature of 23 +/- 3˚C relative humidity of 50 +/- 10% for 12 hours, day and night. The experimental animals were reared in a conventional environment, and the animal feed was freely fed and the cage Replace every three days. Ginseng saponin metabolite F2 application and oral administration method was diluted to distilled water to the final concentration of 200mg / ㎏ and applied to the lesion site of the mouse 0.1ml per 10g mouse weight, using the mouse sonde daily Administration was oral once at a defined time. In addition, Dexamethasone (DEXA, Sigma) used as a positive control was also prepared in the same concentration as F2 and treated in mice. In the case of the negative control group (Vehicle), purified water was applied and orally administered 0.1 ml per 10 g of mouse body in the same manner. Each experimental group is shown in the following [Table 2], and there are 8 rats in each group (n = 8), and the experimental results in each experiment below are the arithmetic mean values of these results.

Table 2 Isolation of Experiment Group

A. Visual observation and scratch count

The results of inflammatory disease-induced mouse model activity including atopic dermatitis and immune hypersensitivity of the ginseng saponin metabolite F2 are shown in FIG. 2.

When observed visually, atopy-induced mice had slower hair growth and slower inflammation than late atopy-induced mice. However, the group treated with ginseng saponin metabolite F2 after the induction of inflammatory diseases including atopic dermatitis and immune hypersensitivity reactions recovered faster than the treated group treated with purified water and the positive control group dexamethasone. Also, the time for hair growth was advanced.

In addition, a magnetic bar (1 mm in diameter, 3 mm long) was inserted after anesthesia (Ketamine + Rompun = 3: 1) on both sides of the mouse Fuji before inducing atopy. Atopy was induced in the mouse after insertion, and the number of scratches was measured to confirm that induction was confirmed. Dexamethasone and ginseng saponin metabolite F2 were applied orally, and the microAct (Neuroscience, Tokyo, Japan) was used to measure the number of scratches.

At 0 weeks immediately after inducing atopic dermatitis, the number of scrapings of mice was significantly increased. As a result, it was confirmed that atopic dermatitis was well induced and began to administer the test substance. As shown in Table 3 and FIG. 3, the group treated with ginseng saponin metabolite F2 and the positive control group showed a significant decrease compared to the negative control group at 2 weeks after application of the test substance.

[Table 3] Result of measuring the number of scratches

B. Histological Observation

As shown in FIG. 4, in the histologic findings of the H & E staining method, the atopic dermatitis group mice showed a severe inflammatory state of the skin surface and morphologically broken skin barriers compared to the atopic non-induced mice. However, in the group treated with ginseng saponin metabolite F2 for 2 weeks after atopic induction, the inflammatory state of the skin surface was similar to the atopic non-induced group, and the skin barrier was not broken. In addition, as a result of measuring the thickness of the skin epidermal layer in Table 4 and Figure 5 below, the ginseng saponin metabolite F2 is purified water in the inflammation-induced mice as a control in mice that induced inflammatory diseases including atopic dermatitis and immune hypersensitivity reactions It was confirmed that there is a more excellent effect than the group treated with and the group treated with dexamethasone applied and administered a positive control group.

[Table 4] Mouse skin thickness measurement results

< Example  3> atopic dermatitis and Immune hypersensitivity  inclusive Inflammatory diseases  In serum in mouse models IgE  Concentration reduction effect

After the F2 treatment using the serum of the mouse was confirmed the effect of reducing the concentration of IgE (Immunoglobulin E), an immune antibody associated with inflammatory diseases including atopic dermatitis and immune hypersensitivity reactions.

In Example 2, serum IgE concentrations of NC / Nga mice (7 weeks old, males, 8 mice each, Daehan Biolink) treated in the same manner as the experimental group were measured by enzyme-linked immunosorbentassay. IgE was injected into each well of 96 wellplate by mixing 1 μL (1/50 dilution) of serum collected from NC / Nga mice with 49 μL of dilution buffer (BD OptEIA Kit, Cat No: 51-2641KC) from BD Biosciences. Each was placed at 25 ° C. for 2 hours at room temperature, washed twice with 300 μL of washing buffer (PBS with 0.05% Tween-20, BD Bioscience), and then placed in antibody biotin-IgE conjugated (BD Bioscience) for 2 hours. After washing twice with water, washed with buffer solution (PBS with 0.05% Tween-20, BD Bioscience), treated with antibody Avidin-HRP conjugeted 100 μL (BD Bioscience), and placed at room temperature for 1 hour, followed by washing buffer (PBS with 0.05% Tween-20, BD Bioscience). Subsequently, BD Biosciences Inc. Substrate A (BD OptEIA Kit, Cat No: 51-2606KZ) and Substrate B (BD OptEIA Kit, Cat No: 51-2607KZ) were mixed in the same amount, and the mixed solution was dispensed in 100 μL and placed in the cow. After leaving for 30 minutes, 100 μL of stop solution (BD OptEIA Kit, Cat No: 51-2608KZ) was treated and the absorbance of IgE was measured at ELISA leader450 nm. The results are shown in FIG. 6 and Table 5.

Table 5 Measurement Result of IgE Concentration in Mouse Serum

From the above results, it was confirmed that ginseng saponin metabolite F2 has an effect of reducing the concentration of IgE in serum increased through atopic induction.

< Example  4> immune related inflammatory cytokines ( Cytokine ) Expression level confirmation

The levels of inflammatory cytokines, IFN-γ and IL-4, were measured by enzyme-linked immunosorbentssay. In Example 2, 1 μL (1/50 dilution) of serum collected and 49 μL of dilution buffer were collected from the mice treated in the same manner as the experimental group, and then dispensed into each well of a 96 well plate. Each was placed at room temperature for 25 hours at 25 ° C., washed twice with washing buffer (PBS with 0.05% Tween-20, BD Bioscience), and then placed for 2 hours in an antibody biotin conjugated. After washing twice with washing buffer (PBS with 0.05% Tween-20, BD Bioscience), 100 μL of antibody Streptavidin-HRP conjugeted was treated and left at room temperature for 1 hour, followed by washing. Dispense 100 μL of TMB substrate and leave for 30 minutes in the dark, then treat 100 μL of stop solution (BD OptEIA Kit, Cat No: 51-2608KZ) and measure the absorbance of IFN-γ and IL-4 at ELISA leader450 nm. It was. The results are shown in FIGS. 7 and 6, 8 and 7.

Table 6 Result of IFN-γ concentration in mouse serum

Table 7 Measurement Result of IL-4 Concentration in Mouse Serum

These results indicate that ginseng saponin metabolite F2 has an effect of increasing the concentration of IFN-γ involved in cellular immunity, helping B cells produce antibodies, and reducing the concentration of IL-4 which induces humoral immunity. Confirmed.

<Composition Manufacturing example  1> Ginseng Saponin Metabolite  Preparation of external preparation for skin containing F2

A. Ginseng Saponins Metabolite  Cream with F2

A 50 g cream containing ginseng saponin metabolite F2 was prepared with the ingredients and contents as shown in Table A below.

TABLE A

Purified water, triethanolamine and propylene glycol are heated and dissolved at 70 캜, and the fatty acids, oily components, emulsifiers and preservatives 2, 3, 4, 5, 6, 7, 9, 11, and 12 are 70 캜. The solution dissolved by heating with was added to emulsify. After emulsification was completed the solution was cooled to 45 ° C. and ginseng saponin metabolite F2 and flavor (components 1 and 13) were added and dispersed and cooled to 30 ° C. to prepare the title composition.

B. Ginseng Saponins Metabolite  Gel with F2

50 g of gel containing ginseng saponin metabolite F2 was prepared with the ingredients and contents as shown in Table B below.

TABLE B

Purified water, triethanolamine, 1,3 butylene glycol are heated and dissolved at 70 ° C., and the components 2, 3, 4, 6, 8, 9, 10, which are oily fatty acids, oily ingredients, emulsifiers and preservatives, are added to 70 ° C. The solution dissolved by heating to ℃ was added to emulsify. After emulsification was completed the solution was cooled to 45 ° C. and ginseng saponin metabolite F2 and flavor (components 1 and 11) were added and dispersed, followed by cooling to 30 ° C. to prepare the title composition.

<Composition Manufacturing example  2> Ginseng Saponin Metabolite  Preparation of a pharmaceutical composition comprising F2

A. Powder  Produce

Ginseng Saponin Metabolite F2 30 mg

Lactose 100 mg

Talc 10 mg

According to a conventional powder preparation method, the above ingredients are mixed and filled in an airtight cloth to prepare a powder.

B. Preparation of Tablets

Ginseng Saponin Metabolite F2 30 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

C. Preparation of Capsules

Ginseng Saponin Metabolite F2 30 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

D. Preparation of Injection

Ginseng Saponin Metabolite F2 30 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ 12H ₂ O 26 mg

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

E. Liquid  Produce

Ginseng Saponin Metabolite F2 30 mg

10 g per isomer

5 g mannitol

Purified water quantity

According to the conventional method of preparing a liquid solution, each component is added to the purified water to dissolve, the lemon flavor is added appropriately, the above components are mixed, purified water is added, the whole is adjusted to 100 ml by the addition of purified water, and then filled into a brown bottle. The solution is prepared by sterilization.

Simple modifications and variations of the present invention can be easily made by those skilled in the art, and all such modifications or changes can be seen to be included in the scope of the present invention.

Claims (7)

Pharmaceutical composition for improving, alleviating, treating or preventing atopic diseases comprising ginseng saponin metabolite F2 as an active ingredient. The pharmaceutical composition of claim 1, wherein the atopic disease is atopic dermatitis. The pharmaceutical composition of claim 2, wherein the composition is a formulation selected from the group consisting of ointments, gels, creams, patches and sprays. The pharmaceutical composition of claim 2, wherein the composition is an oral or injectable preparation. The method of claim 4, wherein the oral preparation is a powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, suspensions, solvents, emulsions or syrups, wherein the injectable preparation is in the form of a sterile injectable form. Pharmaceutical composition. Cosmetic composition for atopic skin improvement or alleviation comprising ginseng saponin metabolite F2 as an active ingredient. According to claim 6, wherein the cosmetic composition is a flexible cosmetics, astringent cosmetics, nourishing cosmetics, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body A cosmetic composition which is a formulation selected from the group consisting of creams, body oils, body essences, makeup bases, foundations, hair dyes, shampoos, rinses and body cleansers.

Images